Lucid Capital Reaffirms Buy Rating on ADIL
Lucid Capital Markets reiterates its buy rating on ADIL, setting a $6 price target, a 101.34% upside from the current price.
Key Points
- Lucid Capital Markets reiterated its buy rating on ADIL with a price target of $6 on June 15, 2026.
- Lucid Capital Markets's $6 price target implies 101.34% upside from Adial Pharmaceuticals, Inc.'s ($ADIL) current $2.98 share price.
- ADIL shares are trading around $2.98, with insider buying activity observed in April 2026.
- Geode Capital Management and Tower Research Capital increased their holdings in ADIL, while BlackRock slightly reduced its position.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Lucid Capital Markets reaffirmed its positive outlook on ADIL by maintaining a buy rating and setting a price target of $6. This update came on June 15, 2026, from analyst Elemer Piros. Shares of ADIL are currently trading around $2.98.
Other Institutional Activity in ADIL
Geode Capital Management significantly increased its holdings in ADIL, adding 18,019 shares to bring its total to 24,249 shares, valued at approximately $43,405. Tower Research Capital also boosted its stake, adding 1,302 shares for a total of 1,356 shares worth about $2,427. Meanwhile, BlackRock slightly trimmed its position by 1 share, now holding 1,110 shares valued at $1,987.
Insider Buying and Selling at Adial Pharmaceuticals, Inc.
Several insiders at ADIL made notable purchases on April 7, 2026. CEO Claiborne Cary acquired 37,985 shares, and CFO Vinay Shah bought 17,325 shares. COO Tony Goodman also purchased 26,510 shares. These transactions were not part of any pre-planned trading programs.
Analysts Set New Price Targets
On June 15, 2026, Lucid Capital Markets reiterated its buy rating on ADIL with a $6 price target. Previously, Maxim Group upgraded ADIL to a buy with a $1.5 target on September 30, 2025, and Rodman & Renshaw initiated coverage with a buy rating and an $8 target on November 14, 2024.
Bottom Line
Lucid Capital Markets' reaffirmation of its buy rating for ADIL, along with a $6 price target, underscores continued confidence in the company's potential. Investors are keeping an eye on institutional moves and insider activities as indicators of the stock's future performance. Remember, 13F filings and analyst ratings reflect past actions and may not indicate current positions.
Get Adial Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ADIL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.